- Conditions
- Erectile Dysfunction
- Interventions
- tadalafil
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 30 Years to 65 Years · Male only
- Enrollment
- 198 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–13
of 13
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin, oral ERA, oral PDE5 inhibitors
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 88
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
- Conditions
- Erectile Dysfunction, Sexual Dysfunction
- Interventions
- Placebo, Dapoxetine, PDE5I (phosphodiesterase-5 inhibitor)
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 495 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 19
- States / cities
- Decatur, Alabama • Huntsville, Alabama • Englewood, Colorado + 16 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Tadalafil, Sildenafil
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 7 Years to 15 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Riociguat (Adempas, BAY63-2521), Sildenafil, Tadalafil
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Sacramento, California + 14 more
- Conditions
- Nonarteritic Anterior Ischemic Optic Neuropathy
- Interventions
- PDE5 Inhibitors
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Los Altos, California • National City, California + 40 more
- Conditions
- Erectile Dysfunction
- Interventions
- tadalafil once a day [T(OaD)], sildenafil citrate as needed [S(PRN)], tadalafil as needed [T(PRN)]
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 378 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 7
- States / cities
- Huntsville, Alabama • Newport Beach, California • Middlebury, Connecticut + 4 more
- Conditions
- Anterior Ischemic Optic Neuropathy
- Interventions
- Diagnostic procedures
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 40 Years and older · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 11
- States / cities
- Vista, California • Atlantis, Florida • Fort Myers, Florida + 7 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- PDE5 inhibitor, Endothelin Receptor Antagonists
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 13,021 participants
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Erectile Dysfunction
- Interventions
- ASP-001.1, ASP-001, Commercial Sildenafil and Sildenafil/Tadalafil Products
- Device · Drug
- Lead sponsor
- Aspargo Labs, Inc
- Industry
- Eligibility
- 18 Years to 70 Years · Male only
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Ambrisentan, Placebo, Sildenafil, Tadalafil
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 30
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Tadalafil and Sildenafil
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 7 Years to 15 Years · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Fatigue
- Interventions
- Sildenafil, tadalafil, Placebo
- Drug
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 50 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Galveston, Texas